New clinical applications in regenerative medicine are motivating an intense interest in easily accessible sources for producing human stem cells. The 2007 breakthrough showing that induced pluripotent stem cells (iPSC) could be generated directly from adult cells has been a boon to the industry. Since that time, there has been a steady refinement of the cell culture techniques that guide the cell reprogramming process.
Systemic sclerosis, also called scleroderma, progressive systemic sclerosis, or CREST syndrome, is a rare autoimmune connective tissue disease with fibrosis and vasculopathy. Patients often have sclerotic, thickened skin, but some experience significant organ damage. Immunosuppressive therapy is a common approach to patients with systemic sclerosis, but there is a subset of patients that do not respond well to treatment.
A study using peripheral blood mononuclear cells (PBMCs) demonstrates the link between women’s stress levels and shortened telomere length.
Stress is one of the body’s major means of reacting to life challenges, dangers, and difficulties. Various chemicals are released in the body that promote cellular and organ-level changes needed to cope with, adjust, and respond to stressors. The effects that are felt with chronic stress range anywhere from pain, digestive problems, and fatigue to sexual, cognitive, immunological, and emotional effects. Women are particularly vulnerable to the effects of stress due to unique challenges they face, including gender and race-based discrimination and forms of victimization.
Scientists examined the peripheral blood mononuclear cell (PBMC) profiles of patients with and without psoriasis, including those that both responded to classic treatments and didn’t respond. They then analyzed the profile of those immune cell types. Here are the results of that study.
There are often differences among patient populations for a given disease in how effective a treatment provides medical relief. An important part of personalized medicine is identifying patients that are not likely to respond to a treatment regimen for a specific disease or condition. Doing this can limit the loss of time and resources in using ineffective treatments and can allow the use of personalized treatments in these populations.
Researchers believe combining elotuzumab and PBMC treatments with ASCT and lenalidomide maintenance may be an effective treatment option for multiple myeloma.
Multiple myeloma (MM) is a hematological cancer of bone marrow plasma cells. In MM, the antibody-producing plasma cells transform into malignant myeloma cells that produce abnormal antibodies (M proteins). When M proteins accumulate, they outnumber and overcrowd the normal antibodies. Patients with MM can experience bone and kidney damage, anemia, and an impaired immune system.